9 months ago
MedAlliance's Drug-Eluting Balloon Revolutionizes Heart Care
MedAlliance, a company from Switzerland, has made a special balloon that can help people with heart disease without using stents.
This balloon works as well as stents and has been approved in many countries.
MedAlliance was bought by another company for a lot of money, which means more people around the world, including in India, can use this helpful balloon.
MedAlliance's SELUTION Sirolimus Drug-Eluting Balloon (DEB) offers a stentless solution for heart disease treatment
The balloon-based therapy matched the performance of drug-eluting stents in a clinical trial involving over 3,300 patients
MedAlliance was acquired by Cordis for USD 1.135 billion, endorsing its innovative technology
The acquisition expands MedAlliance's global reach, including in India, making safer and more effective cardiovascular therapies accessible
SELUTION SLR™ DEB is commercially available in over 65 countries and under investigation in the U.S.
- Who
- MedAlliance, a Swiss-based innovator, and Cordis (USA)
- What
- Developed and acquired a patented Drug-Eluting Balloon (DEB) for treating heart disease
- Where
- Globally, including India
- When
- October 2023 (acquisition), ongoing clinical trials and commercialization
- Why
- To provide a safer, more effective, and less invasive treatment for coronary artery disease
Key facts
- Technology
- SELUTION Sirolimus Drug-Eluting Balloon (DEB)
- Acquisition Value
- USD 1.135 billion (over ₹10,000 crore)
- Countries Commercially Available
- Over 65
- Clinical Trial Size
- Over 3,300 patients
- Founder
- Amit Bohora
- Conference
- Transcatheter Cardiovascular Therapeutics (TCT) 2025
Quotes
Amit Bohora, Co-Founder of MedAlliance
Co-Founder of MedAlliance, played a pivotal role in guiding the company from early research to worldwide commercialization.
“What began as an idea to rethink stent-based intervention has evolved into a global movement toward stentless treatment. The SELUTION sirolimus-eluting balloon is changing how clinicians approach coronary artery disease–treating patients with less invasive, more natural vessel restoration strategies.”
theprint.in
“The acquisition by Cordis was not merely a transaction, it was a validation of our mission to bring safer, more effective cardiovascular therapies to patients everywhere.”
theprint.in
